Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Entry into a Material Definitive Agreement

Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

Story continues below

On September12, 2018, Supernus Pharmaceuticals,Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Supernus Merger Sub,Inc., a Delaware corporation, which is an acquisition subsidiary formed and wholly owned by the Company (the “Merger Sub”), Biscayne Neurotherapeutics,Inc., a Florida corporation (which, as a condition to closing, must convert to a Delaware corporation) (“Biscayne”), and Reich Consulting Group,Inc., as the securityholder representative (the “Merger”). The Merger is subject to certain closing conditions, including the renegotiation of certain third party intellectual property license agreements. All closing conditions are more fully described in the Merger Agreement and, unless waived by the parties, must occur in order to consummate the Merger. The Company issued a press release describing the Merger, which is described in Item 8.01 of this Current Report on Form8-K and attached as Exhibit99.1 of this Current Report on Form8-K.

to the terms of the Merger Agreement, at the effective time of the Merger, the Merger Sub will merge with and into Biscayne, the separate existence of the Merger Sub will cease and Biscayne will continue as the surviving corporation and will be a wholly owned subsidiary of the Company. The Merger Agreement provides for a cash payment by the Company at the closing of the Merger of approximately $15 million to the current Biscayne securityholders. After the closing of the Merger, the Company will be required to make additional cash payments to the former Biscayne securityholders upon the achievement of certain specified development and sales milestones. These additional payments include: (i)payments of up to approximately $73 million contingent on the Company achieving certain development milestones with respect to the development of certain pharmaceutical intellectual property assets held by Biscayne prior to the Merger; and (ii)payments of up to approximately $95 million contingent on the Company achieving certain sales milestones with respect to the marketing of products developed from such assets. The Company will also pay a low single digit royalty on net sales to the former securityholders of Biscayne and any applicable royalties to third parties for the use of in-licensed intellectual property. The maximum combined royalty the Company will pay to all parties is approximately 12%, depending on the intellectual property covering the marketed product and applicable tiered sales levels.

The Merger Agreement contains customary representations, warranties and covenants by each of the applicable parties to the Merger Agreement, and also contains indemnification provisions under which the parties thereto have agreed to indemnify each other against certain liabilities. The representations, warranties and covenants in the Merger Agreement were made solely for the benefit of the parties to the Merger Agreement and may be subject to limitations agreed upon by the contracting parties. Investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or Biscayne or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company’s public disclosures.

There can be no assurance that the Merger will occur subject to the terms described herein, or at all. Even if the Company consummates the Merger, it may not be able to achieve the expected benefits of the Merger including the development and commercialization of Biscayne’s product candidate for the treatment of epilepsy.

The foregoing description of the Merger and the Merger Agreement is only a summary, does not purport to be complete, and is qualified in its entirety by reference to the Merger Agreement which the Company intends to file as an exhibit to the Company’s Quarterly Report on Form10-Q for the period ended September30, 2018. Unless otherwise defined herein, the capitalized terms used above shall have the same meaning ascribed to them in the Merger Agreement.

Item 8.01 Other Events.

On September13, 2018, the Company issued a press release announcing the Merger. A copy of this press release is furnished as Exhibit99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit

The following document is furnished as an Exhibit to Item 8.01 hereof:

Exhibit99.1 — Press Release Dated September13, 2018.


SUPERNUS PHARMACEUTICALS INC Exhibit
EX-99.1 2 a18-31097_1ex99d1.htm EX-99.1 Exhibit 99.1     Supernus to Acquire Biscayne Neurotherapeutics   Adds Phase 1 Novel Epilepsy Development Program   Rockville,…
To view the full exhibit click here

About Supernus Pharmaceuticals,Inc. (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.

An ad to help with our costs